期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗糖尿病新药维格列汀 被引量：29

Vildagliptin:a new agent for diabetic treatment
下载PDF
导出
摘要 维格列汀(vildagliptin)是继西他列汀(sitagliptin)后的又一个二肽基肽酶-IV(DPP-IV)抑制剂,用于治疗2-型糖尿病。临床研究表明,维格列汀是一个口服有效、市场前景良好的药物,单用或与二甲双胍、胰岛素合用都有明显的降血糖作用,且服用安全,耐受性好,不良反应少。现对其作用机制、药效学、药动学、临床疗效进行综述。 Vildagliptin,another dipeptidyl peptidase-Ⅳ inhibitor after sitagliptin has been marketed,is used for the treatment of type 2 diabetes.It is proved as an orally active and safe agent.Monotherapy and combination with metformin or insulin are efficacious and well tolerated in patients with type 2 diabetes.The action mechanism,pharmacodynamics,pharmacokinetcs,clinic trials of vildagliptin were reviewed in this paper.
作者 樊新星 徐珽 卢静 唐尧
机构地区 四川大学华西医院药剂科
出处 《中国新药杂志》 CAS CSCD 北大核心 2008年第14期1272-1274,共3页 Chinese Journal of New Drugs
关键词 维格列汀 二肽基肽酶-IV(DPP-IV)抑制剂 2-型糖尿病 vildagliptin,dipeptidyl peptidase-IV inhibitor （DPP-IV）,type 2 diabetes
分类号 R977.15 [医药卫生—药品]
  • 相关文献

参考文献15

  • 1PRATLEY RE, SALSALI A, MATFIN G. Inhibition of dipeptidyl peptidase-4 with vildagliptin : a potential new treatment for type 2 diabetes[ J]. Br J Diabetes Vasc Dis,2006,6(4) : 150 - 156.
  • 2VILLHAUER EB, BRINKMAN JA, NADERI GB, et al. 1-[ [ ( 3- hydroxy-1 - adamantyl ) amino ] acetyl ] -2-cyano-( S ) - pyrrolidine : a potent, selective, and orally bioavailable dipeptidyl peptidase Ⅳ inhibitor with antihyperglycemic properties[ J ]. J Med Chem, 2003,46 ( 13 ) :2774 - 2789.
  • 3夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量：26
  • 4MARGUET D, BAGGIO L,KOBAYASHI,et al. Enhanced insulin secretion and inproved glucose tolerance in mice lacking CD26 [ J ]. Proc Natl Acad Sci USA ,2000,97 ( 12 ) :6874 - 6879.
  • 5NAGAKUBA T, YASUDA N,YAMAZAKI K,et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptldyl peptidase Ⅳ- deficient Fischer rats [ J ]. Biochem Biophys Res Commun,2001,284(2 ) :501 - 506.
  • 6HE Y,BALCH A, CAMPESTRINI J, et al. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes [ J ]. Clin Pharmacol Ther,2005,77 ( 2 ) :56.
  • 7HE YL,SABO R,CAMPESTRINI J ,et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase Ⅳ ( DDP-4 ) inhibitor vildagliptin [ J ]. Eur J. Clin Pharm,2007, 63(7) :677 -686.
  • 8PRATLEY RE, JAUFFRET-KAMEL S, GALBREATH E,et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes [ J ]. Horm Metab Res ,2006,38 ( 6 ) :423 - 428.
  • 9RISTIC S, BYIERS S, FOLEY J,et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin ( LAF237 ) dose response [ J ]. Diabetes Obes Metab,2005,7 ( 6 ) : 692 - 698.
  • 10BOSI E,CAMISASCA RP,COLLOBER C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin [ J ]. Diabetes Care, 2007,30(4) :890 - 895.

二级参考文献10

  • 1HERMAN GA,BERGMAN A,STEVENS C,et al.Effect of single oral doses of sitagliptin,a dipeptidyl peptidase-4 inhibitor,on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes[J].J Clin Endocrinol Metab,2006,91 (11):4612-4619.
  • 2BERGMAN AJ,STEVENS C,ZHOU Y,et al.Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin,a dipeptidyl peptidase-Ⅳ inhibitor:a double-blind,randomized,placebo-controlled study in healthy male volunteers[J].Clin Ther,2006,28(1):55 -72.
  • 3HERMAN GA,BERGMAN A,LIU F,et al.Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitaglipin in middle-aged obese subjects[J].J Clin Pharmacol,2006,46(8):876 -886.
  • 4HERMAN GA,STEVENS C,VAN DYCK K,et al.Pharmacokinetics and pharmacodynamics of sitagliptin,an inhibitor of dipeptidyl peptidase Ⅳ,in healthy subjects:results from two randomized,double-blind,placebo-controlled studies with single oral doses[J].Clin Pharmacol Ther,2005,78(6):675 -688.
  • 5VINCENT SH,REED JR,BERGMAN AJ,et al.Metabolism and excretion of the DPP-4 inhibitor[14C] sitagliptin in humans[J].Drug Metab Dispos,2007,35(4):533 -538.
  • 6RAZ I,HANEFELD M,XU L,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitsgliptin as monotherapy in patients with type 2 diabetes mellitus[J].Diabetologia,2006,49(11):2564 -2571.
  • 7ASCHNER P,KIPNES MS,LUNCEFORD JK,et al.Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes[J].Diabetes Care,2006,29(12):2632 -2637.
  • 8SCOTT R,WU M,SCANCHEZ M,et al.Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes[J].Int J Clin Pract,2007,61(1):171 -180.
  • 9CHARBONNEL B,KARASIK A,LIU J,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone[J].Diabetes Care,2006,29(12):2638 -2643.
  • 10ROSENSTOCK J,BRAZG R,ANDRYUK PJ,et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2diabetes:a 24-week,multicenter,randomized,doubleblind,placebo-controlled,parallel-group study[J].Clin Ther,2006,28(10):1556-1568.

共引文献25

同被引文献188

引证文献29

二级引证文献110

中国新药杂志
2008年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部